Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 7-8, 2010, Pages 862-871

  Mäkitalo, Laura ^a   Kolho, Kaija Leena ^b   Karikoski, Riitta ^a   Anthoni, Hannele ^a   Saarialho Kere, Ulpu ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Crohn's disease; Matrix metalloproteinase 10; Matrix metalloproteinase 7; Tissue inhibitor of metalloproteinase 3; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEMATOCHEZIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; POLYPOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; STROMA; ULCERATIVE COLITIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77955704585     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903583863     Document Type: Article

References (42)

1. Geboes K, De Hertogh G. Indeterminate colitis. Inflamm Bowel Dis 2003;9:324-331
2. Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis 2002;8:112-128
3. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004;126: 1550-1560
4. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-697
5. Matsui T, Yao T, Sakurai T, Yao K, Hirai F, Matake H, et al. Clinical features and pattern of indeterminate colitis: Crohn's disease with ulcerative colitis-like clinical presentation. J Gastroenterol 2003;38:647-655
6. Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm Bowel Dis 2006;12:258-262
7. Griffiths AM, Buller HB. Inflammatory bowel disease. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB, editors. Pediatric gastrointestinal diseases, 3rd ed. Hamilton, Ont.: Decker; 2000. p. 613-652
8. Turunen P, Ashorn M, Auvinen A, Iltanen S, Huhtala H, Kolho KL. Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2009;15:56-62.
9. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994;18:165-173 (Pubitemid 24056474)
10. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.
11. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007;13:97-107.
12. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994;47:113-116
13. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117: 814-822
14. Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004;53:701-709
15. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj- Elliott M, Smith JA, Pender SL. Imbalance of stromelysin- 1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57-62.
16. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, Airola K, Parks WC, Karjalainen-Lindsberg ML. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996;148:519-526
17. Stumpf M, Cao W, Klinge U, Klosterhalfen B, Junge K, Krones CJ, et al. Reduced expression of collagen type I and increased expression of matrix metalloproteinases 1 in patients with Crohn's disease. J Invest Surg 2005;18: 33-38
18. Wang YD, Mao JW. Expression of matrix metalloproteinase- 1 and tumor necrosis factor-alpha in ulcerative colitis. World J Gastroenterol 2007;13:5926-5932
19. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998;152:1005-1014
20. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008;40:1334-1347
21. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 2003;38:348-354
22. Rath T, Roderfeld M, Graf J, Wagner S, Vehr AK, Dietrich C, et al. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 2006;12:1025-1035
23. Bamba S, Lee C-Y, Brittan M, Preston SL, Direkze NC, Poulsom R, et al. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J Pathol 2006;209:265-273
24. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase- 1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-246
25. Mäkitalo L, Sipponen T, Kärkkäinen P, Kolho K-L, Saarialho-Kere U. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis 2009;24:1157-1167
26. Kuivanen T, Jeskanen L, Kyllönen L, Impola U, Saarialho- Kere UK. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13 are present in epithelial cells of keratoacanthomas. Mod Pathol 2006;19:1203-1212
27. Isaka K, Nishi H, Nakai H, Nakada T, Feng Li Y, Ebihara Y, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 2003;97:79-89.
28. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-573
29. Bister V, Kolho KL, Karikoski R, Westerholm-Ormio M, Savilahti E, Saarialho-Kere U. Metalloelastase (MMP-12) is upregulated in the gut of pediatric patients with potential celiac disease and in type 1 diabetes. Scand J Gastroenterol 2005;40:1413-1422
30. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, et al. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 2002;41:9462-9469
31. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006;231:20-27
32. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase- 7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2000; 105:143-150
33. Madlener M, Mauch C, Conca W, Brauchle M, Parks WC, Werner S. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J 1996;320: 659-664 (Pubitemid 26417794)
34. Kobayashi K, Arimura Y, Goto A, Okahara S, Endo T, Shinomura Y, et al. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol 2006;209:376-383
35. Freour T, Jarry A, Bach-Ngohou K, Dejoie T, Bou- Hanna C, Denis MG, et al. TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. Int J Mol Med 2009;23:41-48
36. Cesaro A, Abakar-Mahamat A, Brest P, Lassalle S, Selva E, Filippi J, et al. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 2009;296: G1332-43.
37. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435:39-44.
38. Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T, Nagura H. Vascular smoothmuscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 2001;39:50-59
39. Pirila E, Ramamurthy NS, Sorsa T, Salo T, Hietanen J, Maisi P. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci 2003;48:93-98
40. Ganguly K, Swarnakar S. Induction of matrix metalloproteinase- 9 and -3 in nonsteroidal anti-inflammatory druginduced acute gastric ulcers in mice: regulation by melatonin. J Pineal Res 2009;47:43-55.
41. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, et al. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP- 28, in normal and inflamed intestine and colon cancer. Dig Dis Sci 2004;49:653-661
42. Pache I, Rogler G, Felley C. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med Wkly 2009;139: 278-287